Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice Non-Interventional Phase 4 Study
Aims: The purpose of this study is to assess the incidence of adverse events in migraine patients with long-term exposure to fremanezumab relative to migraine patients treated with non-fremanezumab preventive migraine pharmacotherapy targeting the calcitonin gene-related peptide (CGRP) pathway or other preventive migraine pharmacotherapy not targeting the CGRP pathway. A primary objective of the study is to evaluate the long-term safety of fremanezumab in all patients with migraine through evaluation of incidence of all adverse events. The second primary objective of the study is to evaluate the safety of fremanezumab in a sub-population of cardiovascular compromised patients and/or with migraine with regard to cardiovascular events and major adverse cardiovascular events.
Principal Investigator: Steven Meyers, MD
NorthShore Project Number: EH20-351
Contact: Call 847.503.4344 with questions regarding the study
Open to enrollment: Yes